Results 301 to 310 of about 61,480 (319)

Genetic polymorphisms of CYP3A4: CYP3A4⁎18 allele is found in five healthy Malaysian subjects

Clinica Chimica Acta, 2007
Cytochrome P450 3A4 (CYP3A4) is the major cytochrome involved in metabolizing of >60% of all drugs used in humans. A number of allelic variations in CYP3A4 gene are known to affect catalytic activity including CYP3A4*4, CYP3A4*5 and CYP3A4*18. We investigated the frequencies of CYP3A4*4, CYP3A4*5 and CYP3A4*18 alleles in a Malaysian population.
A B, Ruzilawati, A W Mohd, Suhaimi, S H, Gan   +2 more
openaire   +2 more sources

Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2D6, CYP3A4 and CYP1A2 and antipsychotics

European Journal of Human Genetics, 2023
L. Beunk, M. Nijenhuis, Bianca Soree, Nienke J. de Boer-Veger, Anne M Buunk, H. Guchelaar, E. Houwink, A. Risselada, G. Rongen, R. V. van Schaik, J. Swen, D. Touw, R. van Westrhenen, V. Deneer, J. van der Weide   +14 more
semanticscholar   +1 more source

Identification and characterization of CYP3A4*20, a novel rare CYP3A4 allele without functional activity

Clinical Pharmacology & Therapeutics, 2006
The major drug-metabolizing enzyme cytochrome P450 (CYP) 3A4 is genetically conserved. One outlier of Brazilian descent was found in a clinical pharmacokinetic trial exhibiting a 6-fold higher exposure than expected to an investigational drug, shown to be a CYP3A4 substrate.
Anna, Westlind-Johnsson, Robert, Hermann, Andreas, Huennemeyer, Bernhard, Hauns, Gezim, Lahu, Nassr, Nassr, Karl, Zech, Magnus, Ingelman-Sundberg, Oliver, von Richter   +8 more
openaire   +2 more sources

CYP3A4*1G regulates CYP3A4 intron 10 enhancer and promoter activity in an allelicdependent manner

Int. Journal of Clinical Pharmacology and Therapeutics, 2015
CYP3A4*1G (G > A) in human CYP3A4 intron 10 is associated with therapeutic effects of CYP3A4-metabolized drugs. The aim of this study was to predict its function in the regulation of CYP3A4 expression.Functional analysis of the CYP3A4*1G allele was performed using bioinformatic methods and enhancer or promoter reporter assays in HepG2 cells ...
Weihong, Yang, Dengzhi, Zhao, Shengna, Han, Zengyuan, Tian, Liang, Yan, Guoqiang, Zhao, Quancheng, Kan, Wei, Zhang, Lirong, Zhang   +8 more
openaire   +2 more sources

Modelling atypical CYP3A4 kinetics: principles and pragmatism

Archives of Biochemistry and Biophysics, 2005
The Michaelis-Menten model, and the existence of a single active site for the interaction of substrate with drug metabolizing enzyme, adequately describes a substantial number of in vitro metabolite kinetic data sets for both clearance and inhibition determination.
Houston, J. Brian, Galetin, Aleksandra
openaire   +3 more sources

Tiamulin inhibits human CYP3A4 activity in an NIH/3T3 cell line stably expressing CYP3A4 cDNA

Biochemical Pharmacology, 1995
Tiamulin is an antibiotic frequently used in veterinary medicine. The drug has been shown to produce clinically important interactions with other compounds that are administered simultaneously. An NIH/3T3 cell line, stably expressing human cytochrome P450 (EC 1.14.14.1) cDNA (CYP3A4), was used to study the effect of tiamulin on CYP3A4 activity.
E M, De Groene, S M, Nijmeijer, G J, Horbach, R F, Witkamp   +3 more
openaire   +2 more sources

Homology modelling of CYP3A4 from the CYP2C5 crystallographic template: analysis of typical CYP3A4 substrate interactions

Xenobiotica, 2004
1. The results of homology modelling of cytochrome P4503A4 (CYP3A4), which is a human enzyme of major importance for the Phase 1 metabolism of drug substrates, from the CYP2C5 crystal structure is reported. 2. The overall homology between the two protein sequences was generally good (46%) with 24% of amino acid residues being identical and a 22 ...
D F V, Lewis, B G, Lake, M, Dickins, P S, Goldfarb   +3 more
openaire   +2 more sources

CYP3A4Intron 6 C>T SNP (CYP3A4*22) Encodes Lower CYP3A4 Activity in Cancer Patients, as Measured with Probes Midazolam and Erythromycin

Pharmacogenomics, 2013
The CYP3A4*22 allele was recently reported to be associated with reduced CYP3A4 activity. We investigated the impact of this allele on the metabolism of the CYP3A-phenotyping probes, midazolam (MDZ) and erythromycin.Genomic DNA from 108 cancer patients receiving intravenous MDZ and 45 undergoing the erythromycin breath test was analyzed for CYP3A4*22 ...
Elens, Laure, Nieuweboer, Annemieke, Clarke, SJ, Charles, KA, Graan, Anne-joy, Haufroid, V, Mathijssen, RHJ, van Schaik, Ron   +7 more
openaire   +3 more sources

Systematic screening for CYP3A4 genetic polymorphisms in a Han Chinese population.

Pharmacogenomics (London), 2017
G. Hu, D. Dai, Hao Wang, Xiang‐xin Huang, Xiao-yang Zhou, Jie Cai, Hao Chen, J. Cai   +7 more
semanticscholar   +1 more source

The combination of CYP3A4*22 and CYP3A5*3 single-nucleotide polymorphisms determines tacrolimus dose requirement after kidney transplantation

Pharmacogenetics & Genomics, 2017
N. Lloberas, L. Elens, Inés Llaudó, A. Padullés, T. van Gelder, D. Hesselink, H. Colom, F. Andreu, J. Torras, O. Bestard, Josep M. Cruzado, S. Gil‐Vernet, R. V. van Schaik, J. Grinyó   +13 more
semanticscholar   +1 more source